Xeris Pharmaceuticals Inc. (XERS) Tops Q4 EPS by 5c; Offers Guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.10), $0.05 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $33.14 million versus the consensus estimate of $31.04 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2023 revenue of $135-165 million, versus the consensus of $152.3 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Colony Bankcorp to acquire First Reliance in $163M stock-and-cash deal
• Currenc Group suspends Indonesian WalletKu unit operations